HLA DR15 and Immunobiologic Outcomes

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 3, 2007, Pages 371-

  Battiwalla, Minoo ^a   Hahn, Theresa ^a   McCarthy Jr , Philip L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; HLA DR15 ANTIGEN; HLA DR4 ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; HEMATOLOGIC MALIGNANCY; HLA TYPING; HUMAN; IMMUNOBIOLOGY; INCIDENCE; LETTER; MORTALITY; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; RISK FACTOR;

CELL SURVIVAL;

EID: 33847049787     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.12.439     Document Type: Letter

References (4)

1. Stern M., Passweg J., Tiercy J.M., et al. Human leukocyte antigen DR15 Is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12 (2006) 1169-1175
2. Battiwalla M., Hahn T., Radovic M., et al. Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood 107 (2006) 1970-1973
3. Aggarwal C., Gupta S., Hahn T., Padmanabhan S., McCarthy P.L., and Battiwalla M. Human leukocyte antigen (HLA) DR4 is associated with inferior progression free survival (PFS) following allogeneic hematopoietic stem cell transplantation (allo HSCT) for lymphoid malignancies. Proc ASCO 24 (2006) 6543 [Abstract]
4. Gupta S., Aggarwal C., Hahn T., Padmanabhan S., McCarthy P., and Battiwalla M. Human leukocyte antigen (HLA) DR4 is not associated with differences in overall survival (OS), progression free survival (PFS), or graft-vs-host-disease (GVHD) following allogeneic hematopoietic stem cell transplantation (allo HSCT) for myeloid malignancies. Proc ASCO 24 (2006) 6552 [Abstract]